People not generally eligible for GLP-1s at higher doses
Many patients travel with their prescribed injectable tirzepatide
Reported effects Exceptional weight loss (average 2224% in obesity trials) Significant glycemic control for type 2 diabetes (HbA1c reductions of 1.32.0%) Improved cardiometabolic markers (reduced blood pressure, LDL cholesterol, waist circumference) Resolution of hepatic steatosis (liver fat) in over 80% of cases with high doses Universal response with 100% of participants achieving at least 5% weight reduction on higher doses Reported side effects Nausea (mild-to-moderate, most common) Vomiting (mild-to-moderate) Diarrhea (mild-to-moderate) Gastrointestinal symptoms primarily occur during dose escalation Side effects are dose-dependent and transient No severe hypoglycemia or serious treatment-related adverse events reported Storage Lyophilised (unmixed) Store at -20 C (-4 F) or colder in dry, dark conditions for up to 24 months
Estes peptdeos se ligam a receptores acoplados protena G, ativando uma srie de mecanismos que promovem a secreo de insulina dependente de glicose, reduzem a secreo de glucagon, estimulam a liplise, retardam o esvaziamento gstrico e aumentam a saciedade, contribuindo assim para a perda de peso
How Genetic Testing Personalizes Your Semaglutide Timeline PlexusDx's Precision Peptide Genetic Test maps variants in key weight-regulation pathways, including the GLP1R gene (rs6923761), GIPR gene (rs1800437), and MC4R gene (rs17782313)
J., Donahoo, W
